
Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.

Huntington’s disease (HD) is a rare and incurable hereditary condition of the central nervous system. The condition can cause involuntary …

Wave Life Sciences (NASDAQ: WVE) has announced that it has received orphan drug designation for the US Food and Drug …
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia

